Skip to main content
Heart & circulationSelective vasopressin V1a agonist

Selepressin

Also known as: FE-202158

By the Peptide Dossier Editorial TeamUpdated How we source

Selepressin was an investigational V1a-selective vasopressor for septic shock. Its adaptive SEPSIS-ACT program stopped for futility without improvement in the primary or key secondary outcomes.

Quick Facts

Class:Selective vasopressin V1a agonist
US product context:Investigational; developmentdiscontinued; not FDA-approved.
Evidence context:SEPSIS-ACT stopped for futility without primary orkeysecondary benefit.

Identity and development

Ferring developed selepressin as FE-202158 for continuous IV infusion in intensive care. It was designed as a selective vasopressin V1a agonist rather than the broader receptor activity of natural vasopressin. Development has been discontinued and no approval was obtained.

Sources: [1]

Selective vasoconstriction rationale

V1a activation constricts blood vessels and raises pressure. The development goals were to preserve this pressor action, avoid V2-related fluid retention and other effects, and reduce reliance on catecholamines such as norepinephrine. Those mechanistic goals did not translate into demonstrated outcome benefit.

Approval and clinical outcomes

Selepressin remains unapproved and its program stopped. The adaptive Phase IIb/III SEPSIS-ACT trial in septic shock was terminated for futility. Ventilator- and vasopressor-free days, the primary endpoint, did not significantly differ from placebo. Key secondary outcomes, including 90-day mortality, were also not improved.

A companion design paper describes the adaptive methods, but methodological innovation does not reverse the negative efficacy result.

Sources: [2]

References and further reading

This reference draws on Superpower’s Peptide Library and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .

  1. 10.1001/jama.2019.14607Identity and developmentCited in: Identity and development
  2. 10.1513/AnnalsATS.201708-669SDApproval and clinical outcomesCited in: Approval and clinical outcomes

Frequently Asked Questions About Selepressin

Related Peptides

NangibotidePegcetacoplanAlbiglutideAngiotensin II

Continue exploring Selepressin

Search all related references →

Our library review is ongoing. Read how we evaluate evidence or report a correction.

Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.